NASDAQ:AUTL - US05280R1005 - ADR
The current stock price of AUTL is 1.6 USD. In the past month the price decreased by -33.47%. In the past year, price decreased by -59.03%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.75 | 369.42B | ||
AMGN | AMGEN INC | 13.18 | 154.80B | ||
GILD | GILEAD SCIENCES INC | 14.78 | 141.90B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 22.96 | 99.70B | ||
REGN | REGENERON PHARMACEUTICALS | 12.87 | 62.25B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
ARGX | ARGENX SE - ADR | 76.17 | 43.22B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.07 | 35.72B | ||
INSM | INSMED INC | N/A | 28.08B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.64B | ||
NTRA | NATERA INC | N/A | 22.58B | ||
BIIB | BIOGEN INC | 8.51 | 19.97B |
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The company is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. The company has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
AUTOLUS THERAPEUTICS PLC
The Mediaworks, 191 Wood Lane
London W12 7RZ GB
CEO: Christian Itin
Employees: 649
Phone: 442038296230
The current stock price of AUTL is 1.6 USD. The price decreased by -0.62% in the last trading session.
The exchange symbol of AUTOLUS THERAPEUTICS PLC is AUTL and it is listed on the Nasdaq exchange.
AUTL stock is listed on the Nasdaq exchange.
17 analysts have analysed AUTL and the average price target is 9.65 USD. This implies a price increase of 503.08% is expected in the next year compared to the current price of 1.6. Check the AUTOLUS THERAPEUTICS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AUTOLUS THERAPEUTICS PLC (AUTL) has a market capitalization of 425.83M USD. This makes AUTL a Small Cap stock.
AUTOLUS THERAPEUTICS PLC (AUTL) currently has 649 employees.
AUTOLUS THERAPEUTICS PLC (AUTL) has a support level at 1.6 and a resistance level at 2.23. Check the full technical report for a detailed analysis of AUTL support and resistance levels.
The Revenue of AUTOLUS THERAPEUTICS PLC (AUTL) is expected to grow by 475.44% in the next year. Check the estimates tab for more information on the AUTL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AUTL does not pay a dividend.
AUTOLUS THERAPEUTICS PLC (AUTL) will report earnings on 2025-11-10, before the market open.
AUTOLUS THERAPEUTICS PLC (AUTL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.85).
The outstanding short interest for AUTOLUS THERAPEUTICS PLC (AUTL) is 6.63% of its float. Check the ownership tab for more information on the AUTL short interest.
ChartMill assigns a fundamental rating of 3 / 10 to AUTL. While AUTL seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months AUTL reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS increased by 27.35% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -31.59% | ||
ROE | -65.74% | ||
Debt/Equity | 0.71 |
17 analysts have analysed AUTL and the average price target is 9.65 USD. This implies a price increase of 503.08% is expected in the next year compared to the current price of 1.6.
For the next year, analysts expect an EPS growth of -0.83% and a revenue growth 475.44% for AUTL